津药达仁堂集团股份有限公司 关于 2024年第三次独立董事专门会议决议 津药达仁堂集团股份有限公司于 2024年9月10日以通讯方式召 开 2024 年第三次独立董事专门会议。会议应参会独立董事 3人,实 际参会独立董事3人,会议由独立董事杨木光先生召集并主持。会议 的通知、召开、表决程序符合法律、法规、规范性文件的规定,会议 合法有效。 根据中国证监会《上市公司独立董事管理办法》、《上市公司治理 准则》,上海证券交易所《股票上市规则》和新加坡交易所有关规则、 本公司《公司章程》与《公司独立董事制度》等相关规定,作为公司 独立董事,我们在事前对本事项进行认真研究,基于独立判断的立场, 发表独立意见。会议形成如下决议： 一、会议审议通过了"公司对津药太平医药有限公司增资暨签订 《津药达仁堂集团股份有限公司对津药太平医药有限公司的增资协 议》的关联交易议案"。 1、公司与天津市医药集团有限公司、津药太平医药有限公司均 为关联关系,鉴于此,相关关联董事回避表决本项议案。 2、该议案是履行新加坡交易所《上市手册》的要求,内容合法、 有效,不存在违反现行有效的法律、法规和规范性文件强制性规定的 情形。 3、我们同意将该 ...

本资产评估报告依据中国资产评估准则编制 津药达仁堂集团股份有限公司 拟对天津中新医药有限公司实施重组涉及 天津中新医药有限公司 股东全部权益价值项目 资产评估报告 国融兴华评报字[2024]第 040090 号 (共一册第一册) 评估机构名称:北京国融兴华 有限责任公司 评估报告日:2024年 ith and · 002 中国资产评估协会 资产评估业务报告备案回执 | 报告编码: | 1111020056202401193 | | --- | --- | | 合同编号: | 国 、 、 （ 2024） 040096 | | 报告类型: | 法定评估业务资产评估报告 | | 报告文号: | 国融兴华评报字 2024 第040090号 | | 报告名称: | 津菇认仁堂集团股份有限公司拟对大津中新医药有 限公司实施重组涉及的天津中新医药有限公司股东 | | | 全部权益价值项目 | | 评估结论: | 493.617.746.39元 | | 评估报告日: | 2024年07月08日 | | 评估机构名称: | 北京国融兴华资产评估有限责任公司 | | | 会员编号:11200391 郭聚彦 (资产评估师) | | ...

证券代码：600329 证券简称：达仁堂 公告编号：2024-030 号 津药达仁堂集团股份有限公司 关于召开 2024 年第一次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一) 股东大会类型和届次 2024 年第一次临时股东大会 召开的日期时间：2024 年 10 月 29 日 14 点 00 分 召开地点：中国天津市南开区白堤路 17 号达仁堂大厦会议室 (五) 网络投票的系统、起止日期和投票时间。 (二) 股东大会召集人：董事会 (三) 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 (四) 现场会议召开的日期、时间和地点 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2024 年 10 月 29 日 至 2024 年 10 月 29 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15:00； ...

证券代码：600329 证券简称：达仁堂 编号：临 2024-028 号 津药达仁堂集团股份有限公司 关于对津药太平医药有限公司增资的关联交易公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、关联交易概述 为解决上市公司与控股股东之间存在的同业竞争问题，提升上市 公司盈利指标，同时进一步发挥商业板块的规模效应，公司拟将旗下 1 本公司拟将所属全资子公司天津中新医药有限公司的全部股权作价，以 增资形式装入公司控股股东天津市医药集团有限公司所属全资子公司 津药太平医药有限公司，并签署《津药达仁堂集团股份有限公司对津药 太平医药有限公司的增资协议》。本次交易金额为 49,361.77 万元人民 币。 本次交易构成关联交易。郭珉、张铭芮、毛蔚雯作为关联董事回避了该 议案的表决。 本次交易未构成重大资产重组，本次交易尚须提交股东大会审议。 过去 12 个月，公司与同一关联人医药集团及其下属公司发生接受劳务、 提供劳务、出租房屋、承租房屋设备、购买资产等类交易，累计交易金 额 1,843.32 万元，占公司最近一期 ...

津药达仁堂集团股份有限公司于 2024 年 9 月 10 日以现场结合通 讯方式召开了 2024 年第五次董事会会议。本次会议应参加董事 9 人， 实参加董事 9 人。会议召开符合《公司法》、《证券法》和《公司章程》 有关召开董事会会议的规定。会议形成如下决议： 一、审议通过了公司对津药太平医药有限公司增资暨签订《津药 达仁堂集团股份有限公司对津药太平医药有限公司的增资协议》的关 联交易议案。（详见临时公告 2024-028 号） 本议案已经公司 2024 年第三次独立董事专门会议审议通过。 证券代码：600329 证券简称：达仁堂 编号：临 2024-027 号 津药达仁堂集团股份有限公司 2024 年第五次董事会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 公司董事郭珉、张铭芮、毛蔚雯作为关联董事，回避表决此议案。 公司董事郭珉、张铭芮、毛蔚雯作为关联董事，回避表决此议案。 表决结果：同意 6 票，反对 0 票，弃权 0 票 二、审议通过了根据新加坡交易所《上市手册》，公司与天津市 医药集团有限公司就增资完成后 ...

证券代码：600329 证券简称：达仁堂 编号：临 2024-026 号 本次按持股比例同比例增资完成后，公司持有财务公司的股权比 例仍为 30%。 医药集团是公司控股股东，同时也是天津药业集团有限公司与天 津金益投资有限公司的控股股东。因此，公司与医药集团、天津药业 集团有限公司、天津金益投资有限公司均形成关联关系。 一、关联交易概述 天津医药集团财务有限公司（以下简称"财务公司"）是由天津 市医药集团有限公司（以下简称"医药集团"）、津药达仁堂集团股份 有限公司（以下简称"公司"）、天津药业集团有限公司与天津金益投 资有限公司共同投资设立的非银行金融机构，四方股东的持股比例分 1 本公司作为天津医药集团财务有限公司的股东方之一，拟与其各方股东 一同按现有持股比例向其同比例增资。公司本次向其增资金额为 1.5 亿 元人民币。 本次交易构成关联交易。郭珉、张铭芮、毛蔚雯作为关联董事回避了该 议案的表决。 本次交易未构成重大资产重组，本次交易无须提交股东大会审议。 过去 12 个月，公司与同一关联人医药集团及其下属公司发生接受劳务、 提供劳务、出租房屋、承租房屋设备、购买资产等类交易，累计交易金 额 1,843 ...

Meeting Details - The meeting is scheduled for September 3, 2024, from 15:00 to 16:30 [2] - The location for the meeting is an online platform, specifically the Panoramic Roadshow [2] - Investors can submit questions via email to drt600329@163.com by August 30, 2024, at 17:00 [3] Participants - Key attendees include Chairwoman Zhang Mingrui, General Manager Wang Lei, Independent Director Representative, Chief Financial Officer Ma Jian, and Board Secretary Jiao Yan [3] Participation Method - Investors can participate directly through the online platform during the meeting time [4] - The company will respond to common investor inquiries within the scope of information disclosure [4] Contact Information - Contact persons are Wang Jian and Jiang Ling [4] - Phone number: 022-27020892 [4] - Email: drt600329@163.com [4] Additional Information - After the meeting, investors can view the meeting details and main content on the Panoramic Roadshow platform [4] - The announcement is made by the Board of Directors of Tianjin Pharmaceutical Darentang Group Co., Ltd. on August 28, 2024 [4]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected stock price increase of over 15% relative to the industry index within the next six months [5][14]. Core Insights - The company reported a stable growth in industrial revenue for Q2 2024, with a year-on-year increase of 4.1% in industrial revenue, despite a decline in overall revenue due to a significant drop in commercial revenue [2]. - The gross margin improved by 3.4 percentage points in Q2 2024, although net profit margin decreased by 2.1 percentage points to 14.3% due to reduced investment income [2]. - The company is focusing on channel penetration and regional expansion to enhance sales of key products, with notable growth in provinces like Guangdong and Jiangsu [2]. Financial Performance Summary - For H1 2024, the company achieved revenue of 3.96 billion yuan, a year-on-year decline of 3.0%, and a net profit of 660 million yuan, down 9.0% year-on-year [1]. - The projected revenue for 2024 is 8.987 billion yuan, with a year-on-year growth rate of 9.3%, and net profit is expected to reach 1.178 billion yuan, reflecting a growth rate of 19.3% [1][10]. - The company's EPS is projected to increase from 1.28 yuan in 2023 to 1.53 yuan in 2024 [10]. Revenue and Profitability Metrics - The company's operating income for 2022 was 8.249 billion yuan, with a net profit of 862 million yuan, while the 2023 figures show a slight decline in revenue to 8.222 billion yuan but an increase in net profit to 987 million yuan [9]. - The expected operating income for 2025 is 9.725 billion yuan, with a net profit forecasted at 1.401 billion yuan [9][10]. - The return on equity (ROE) is projected to improve from 14.6% in 2023 to 17.4% in 2024 [10].

Investment Rating - The investment rating for the company is not explicitly stated in the report, but it indicates a neutral outlook for the stock performance relative to the market index over the next six months [10][13]. Core Insights - The company reported a revenue of 3.97 billion yuan for the first half of 2024, a decrease of 3.0% year-on-year, and a net profit attributable to shareholders of 658 million yuan, down 9.0% year-on-year [3]. - The company has shown a strong performance in its main products, particularly in Guangdong and Jiangsu provinces, with significant growth in sales for key products [3]. - The gross profit margin improved to 49.93%, an increase of 3.07 percentage points, with traditional Chinese medicine products achieving a gross margin of 60.26% [3]. - The company has implemented 128 cost-reduction projects, leading to a 2.7% increase in overall equipment efficiency and a projected 13.6% decrease in energy consumption [3]. - The company is actively pursuing secondary development of existing drugs, with 25 papers published in the first half of 2024, including 7 in SCI journals [3]. Summary by Sections Financial Performance - Revenue for the first half of 2024 was 3.97 billion yuan, a decrease of 3.0% year-on-year [3]. - Net profit attributable to shareholders was 658 million yuan, down 9.0% year-on-year, while the net profit excluding non-recurring items was 634 million yuan, a decrease of 11.0% [3]. - The company achieved a gross profit margin of 49.93%, up 3.07 percentage points, with traditional Chinese medicine products showing a gross margin of 60.26% [3]. Business Development - The commercial segment generated 1.58 billion yuan in revenue, a decline of 14.5%, influenced by the diversification of the business model post-pandemic [3]. - The industrial segment reported revenue of 2.62 billion yuan, reflecting a growth of 4.25% [3]. - The company has successfully launched 7 new products and has resumed production of 10 dormant varieties [3]. Future Outlook - The company anticipates continued profit growth, projecting net profits of 1.18 billion yuan, 1.46 billion yuan, and 1.75 billion yuan for 2024, 2025, and 2026, respectively, with corresponding PE ratios of 20x, 16x, and 14x [3].

Investment Rating - The report maintains a "Buy" rating for the company, with a target price indicating a potential upside of 10%-20% over the next six months [6][5]. Core Insights - In H1 2024, the company reported revenue of 3.965 billion yuan, a year-on-year decrease of 3.02%, and a net profit attributable to shareholders of 658 million yuan, down 8.97% year-on-year [1][2]. - The industrial segment achieved a revenue of 2.62 billion yuan, reflecting a growth of 4.25% despite a high base, while the commercial segment saw a decline of 14.5% with a revenue of 1.58 billion yuan [2]. - The company continues to expand its core product channels, with significant growth in terminal development for key products, including a doubling of revenue from Qingyan Diban and extensive outreach for other products [3]. Financial Performance - The gross profit margin for H1 2024 was 49.93%, an increase of 3.07 percentage points year-on-year, while the net profit margin was 16.42%, a decrease of 1.06 percentage points [4]. - The company implemented 128 lean cost reduction projects, resulting in a 2.7% improvement in overall equipment efficiency (OEE) and an expected 13.6% reduction in energy consumption [4]. Revenue and Profit Forecast - Revenue forecasts for 2024-2026 have been revised down from 9.294 billion, 10.472 billion, and 11.820 billion yuan to 8.504 billion, 9.368 billion, and 10.354 billion yuan respectively [5]. - Net profit forecasts for the same period have also been adjusted down from 1.163 billion, 1.379 billion, and 1.649 billion yuan to 1.094 billion, 1.267 billion, and 1.461 billion yuan respectively [5].